Onconova Therapeutics Announces Rigosertib Data Presented At EADV As Late Breaker
Portfolio Pulse from Benzinga Newsdesk
Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB), associated with advanced/metastatic squamous cell carcinoma (SCC), will be presented at the European Academy of Dermatology and Venereology (EADV). The abstract outlines promising results from a study of four patients treated with rigosertib. Two patients achieved complete cutaneous responses of 12 months or more, one patient experienced metastatic disease progression, and one patient remains on study.
October 12, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Onconova Therapeutics' rigosertib shows promising results in a study presented at EADV. This could potentially increase the company's market share in the cancer treatment sector.
The promising results from the study of rigosertib in patients with RDEB-associated SCC could potentially increase the demand for the drug, leading to increased revenues for Onconova Therapeutics. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100